gabexate

gabexate

GI disease A small synthetic non-antigenic protease inhibitor used to prevent pancreatic damage related to ERCP; IV gabexate is associated with ↓ liver enzymes, pancreatic pain, acute pancreatitis. See ERCP.
References in periodicals archive ?
The five variables selected based on clinical experience and the previous knowledge included rTM, gabexate mesylate, nafamostat mesylate, urinastatin and anti-thrombin III, and they were processed by forced-entry method.
Gabexate mesilate inhibits the expression of HMGB1 in lipopolysaccharide-induced acute lung injury.
SP inhibitors will be amongst the most challenging to develop because of their complex role in coagulation and short half-life of molecules that have made it to clinical use thus far, such as gabexate [58].
With the aim of preventing postERCP pancreatitis, on the day of the ERCP procedure, all patients were given 600 mg/day of gabexate mesilate.
Novel strategies targeting HMGB1, such as glycyrrhizin [37], gabexate mesilate [37], ethyl pyruvate [38, 39], and PPAR ligands [40] that interfere with asbestos-mediated inflammation, may prevent or delay ARDs onset and relieve the progress of malignant ARDs.
Synthetic molecules such as nafamostat mesilate (NM), gabexate mesilate (GM), and sivelestat sodium hydrate drastically reduced LPS-induced injury at least partly by inhibiting HMGB1 [170-172].
Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis.
We hypothesize also to stop pancreatic angiogenesis inhibiting mast cell degranulation by means of C-Kit inhibitors or targeting tryptase by means of gabexate mesilate or nafamostat mesilate [42-45].
showed the combined effect of anticoagulant gabexate mesilate and complement protein C5a inhibitory peptide to successfully improve islet transplantation compared to individual use of the drugs in a syngeneic rat transplant model [60].
Gabexate mesylate (FOY) and nafamostat mesilate (6-amidino-2naphthyl p-guanidinobenzoate dimethane sulfonate; FUT) are nonantigenic synthetic serine protease inhibitors that have been used to treat pancreatitis and DIC and as anticoagulants for extracorporeal circulation with hemodialysis [10, 11].
Therefore, most guidelines recommend against the use of immunemodulating therapies in SAP, such as anti-TNF[alpha] therapy (111), gabexate mesilate (112), lexipafant (113) or activated protein C (114).
Effect of nafamostat, gabexate, or gelatin on stabilization and efficacy of EGF.